Skip to main content
. 2022 Apr 9;9(3):919–933. doi: 10.1007/s40744-022-00445-w

Fig. 1.

Fig. 1

Percentage of male and female patients treated with ixekizumab Q4W achieving ACR20/50/70 (a, b), MDA/VLDA (c, d), and DAPSA LDA/DAPSA Remission (e, f) through 156 weeks. Missing data were imputed by mNRI. P values were calculated for proportions of male vs. female responders; *P < 0.05, P < 0.01, P < 0.001. ACR20/50/70 20%, 50%, or 70% improvement from baseline in the American College of Rheumatology criteria; DAPSA Disease Activity Index for Psoriatic Arthritis, LDA low disease activity, MDA minimal disease activity, Ns number of patients in the subgroup, VLDA very low disease activity, Q4W every 4 weeks